RxDoctor Payments Data

Nichole Polin, MD

Cardiovascular Disease · New Orleans, LANPI 1689617805

Payments from drug & device makers

$2,367in general payments, 2019–2025

Across 24 payments — averaging $98.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Pfizer$333
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$92
  • E.r. Squibb & Sons, L.L.C.$64
  • Amgen$59
  • Novo Nordisk$34
  • plus $80 from 4 others

What the payments were for

  • Speaking & faculty fees$1,65070%
  • Food & beverage$71730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,367 in reported general payments places this provider in the 40th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$63,697
Medicare patients
1,400
Services billed
2,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban256$229,075
EntrestoSacubitril/Valsartan191$193,975
JardianceEmpagliflozin179$136,047
Repatha SureclickEvolocumab146$105,536
XareltoRivaroxaban36$29,438
FarxigaDapagliflozin Propanediol29$19,362
NexlizetBempedoic Acid/Ezetimibe28$16,264
Praluent PenAlirocumab21$11,278
VascepaIcosapent Ethyl16$8,158
BrilintaTicagrelor11$6,766
Atorvastatin Calcium463$4,305
Metoprolol Succinate352$3,995
Valsartan93$3,705
Ezetimibe211$3,494
Rosuvastatin Calcium238$2,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$333$229,075256 claims
NovartisEntresto$1,704$193,975191 claims
Esperion Therapeutics, Inc.Nexlizet$12$16,26428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →